Summit Therapeutics plc and Chinese partner Akeso Inc.'s quest to develop a potential global challenger to Merck & Co., Inc.’s blockbuster Keytruda (pembrolizumab) in the advanced or metastatic non-small cell lung cancer (NSCLC) space is poised to expand to the US firm’s most formidable stronghold – as a monotherapy for the first-line treatment of tumors with PD-L1-high expression (PD-L1 TPS (tumor promotion score) >50%).
ASCO: Ivonescimab A New Challenger To Keytruda In 1L, PD-L1-High NSCLC?
Akeso/Summit Release New Head-To-Head Results
Backed by strong progression-free survival results from the China-only, head-to-head HARMONi-2 trial, Akeso/Summit’s ivonescimab could be set to become a global contender against established standard of care Keytruda in first-line, PD-L1-high non-small cell lung cancer.
